Lumakras

Active Ingredient(s): Sotorasib
FDA Approved: * May 28, 2021
Pharm Company: * AMGEN INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Lumakras Overview

Sotorasib, sold under the brand name Lumakras is an anti-cancer medication used to treat non-small-cell lung cancer (NSCLC).[1][2] It targets a specific mutation, G12C, in the protein KRAS which is responsible for various forms of cancer.[3][4] The most common side effects include diarrhea, musculoskeletal pain, nausea, fatigue, liver damage and cough.[1][2] Sotorasib is an inhibitor of the RAS GTP...

Read more Lumakras Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Sotorasib

Recent Lumakras Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Sotorasib
  • Tablet: 120mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Lumakras: (1 result)

Sorted by National Drug Code
  • 55513-488 Lumakras 120 mg Oral Tablet, Coated by Amgen Inc

Other drugs which contain Sotorasib or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 25 July 2021.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA